vidofludimus

Known as: 2-(3-fluoro-3'-methoxybiphenyl-4-carbamoyl)cyclopent-1-enecarboxylic acid, 4SC-101 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
012320102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
BACKGROUND There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the… (More)
Is this relevant?
2013
2013
BACKGROUND Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2013
Review
2013
Several experimental approaches have been utilized, in order to critically examine the roles of IL-17 family members in… (More)
Is this relevant?
2012
2012
Vidofludimus (Vido) is a novel oral immunomodulatory drug that inhibits dihydro-orotate dehydrogenase and lymphocyte… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
BACKGROUND 4SC-101 is a novel dihydroorotate dehydrogenase inhibitor and a blocker of interleukin (IL)-17 secretion with… (More)
Is this relevant?
Review
2012
Review
2012
This review identifies possible pharmacological targets for inflammatory bowel disease (IBD) within the IL-23/IL-17 axis… (More)
  • figure 1
  • figure 2
Is this relevant?
2010
2010
  • Immunotherapy
  • 2010
 
Is this relevant?
2010
2010
BACKGROUND Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for… (More)
Is this relevant?
2010
2010
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?